Yutong Huang

We look for asset- or platform-based partnership to develop more innovative mRNA therapeutics globally. Our Partnering Interests: • Asset Out-licensing: We are seeking partners to out-license the global or regional rights of our pipeline assets of infectious disease and cancer vaccines as well as a protein replacement therapy for autoimmune diseases. • Technology Out-licensing: We are seeking partners who are interested in licensing our proprietary mRNA/saRNA/cirRNA technology, ionizable lipids and targeted LNPs. • Platform Collaborations: We would like to collaborate with companies who are interested in utilizing our end-to-end technology platform to develop mRNA based medicines.